Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

54.78 +0.50 (+0.93%)
Streaming Delayed Price Updated: 2:07 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,067,256
Open 54.53
Bid (Size) 54.78 (300)
Ask (Size) 54.79 (1,100)
Prev. Close 54.28
Today's Range 54.33 - 55.02
52wk Range 42.52 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 4.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗
All three can provide you with solid, consistent income. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property World Trade
News headline image
3 Unpopular Stocks That Concern Us
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory

Performance

YTD
+2.5%
+2.5%
1 Month
+1.1%
+1.1%
3 Month
+20.1%
+20.1%
6 Month
+26.5%
+26.5%
1 Year
-7.2%
-7.2%

More News

Read More
Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout ↗
Via Chartmill
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth ↗
Via Chartmill
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
Via Finterra
Topics Economy Initial Public Offering
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
News headline image
AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Via The Motley Fool
News headline image
Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Dividend Stocks to Buy and Hold For 10 Years ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Buffett Stocks to Load Up On—And 1 to Ditch ↗
Via MarketBeat
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
Via MarketMinute
Topics Economy Intellectual Property
Thursday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
3 Value Stocks That Fall Short
Via StockStory
News headline image
3 S&P 500 Stocks Walking a Fine Line
Via StockStory
Topics Stocks
News headline image
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
News headline image
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
Via MarketMinute
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
Via MarketMinute
Topics Intellectual Property
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 54.78
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 01/30/26 02:07 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 121.74B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 122B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.